Buy opportunity in CVS HealthLook like the stock either completed the correction or just did wave A and is ready to rally. Longby Fomenka4
CVS - weekly chart cycle analysisToday I am going to review the chart for CVS health Corporation on a weekly timeframe. CVS seems to be following in 18 to 19 week cycle and we saw the latest cycle low being formed with the candle reflecting 27 Jan 2020. On 12th Feb 2020, CVS reported earnings that broadly beat the street’s estimates. CVS reported adjusted EPS of $1.73, which beat estimates of $1.68. The company reported revenue of $66.9B, which also beat estimates of $63.97B. The company forecasted annual EPS from $7.04 – $7.17 in 2020, which was in-line with analyst expectations of $7.15 Lets look at what the charts are suggesting. CVS has started the upward move as suggested with the beginning of the cycle over the last couple of weeks after bottoming out around $ 67.81 levels. CVS is in a very bullish intermediate-term cycle pattern with negative momentum. Given these conditions, we would expect short-term sell-offs to be limited to the intermediate Fibonacci support zone beginning at 70.58. There is a likelihood the stock tests 79 by May 2020 Price is inching upwards towards 75-76 levels, which is the first zone of resistance. This level is important resisitance as this reflects previous cycle high (failed upward move) witnessed during Nov 2019 to Mid Jan 2020. Also, this level shows confluence with Fib levels.... 0.786 levels and hence may act as short term resistance . Once this is cleared, next resistance at 81 to 82.5 levels. As indicated in the chart, this is also cycle high and the previous peak levels , where prices failed to hold on and got into a major declining phase. These levels were last witnessed in Nov and Dec 2018. Price should find support around 69 to 71 levels in the short term. For the bears to regain control and for us to revisit our belief, we will require a daily price close below 66.73 If you like what you see, then please share your comments in the box below and share a thumbs up!Longby LoveForCharts115
VISLwatching think may see short after yesterdays power hour run up watching 50 ema and 100 ema on the 15 minby SwingBatter126
CVS is back!After a press release indicating that CVS Health plans to open 600 new Health Hub stores this year, CVS stock has once again been climbing. I suspect the breakout will continue once CVS pushes through some resistance. I'm looking for maybe $78 per share from this run. CVS's forward P/E of about 10.5 is very attractive for a stock with large growth prospects in the next 2 years. We've got a healthcare cost bubble in the USA, and CVS may be on the leading edge of popping that bubble with its low-cost clinic model. It also boasts a roughly 2.5% dividend.Longby ChristopherCarrollSmith1120
Weekly flagwatching for breakout and then will enter calls. Need to buy time as this is a slow mover. Longby Option_Traders116
CVS breached channel top; buy the pullbackCVS has been on a monster run, and today it breached the top of its long-term downward trending parallel channel. CVS is overbought, so it will probably pull back before moving higher, but the channel breach is a bullish signal that strongly suggests the downtrend is over. I expect CVS to see 100 within a year or two.Longby ChristopherCarrollSmithUpdated 1116
CVS - DAILY CHART Hi, today we are going to talk about CVS Health Corp and its current landscape. CVS is poised to receive increasing attention from the market as relevant events are taking place. The healthcare company can be benefited from the implied move that Congress will repeal three key Obamacare aspects related to the health industry taxes as part of fiscal 2020 spending bills. News that can boost CVS next year. Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice. by Igor-Silva29
COMPRA PUT EN 1.81$ CON ACCION EN PRECIO 84.02$ VENCIMIENTO 3 MCOMPRA PUT EN 1.81$ CON ACCION EN PRECIO 84.02$ VENCIMIENTO 3 MESES FEBRERO 21 ...Shortby juancmata3
CVS Long ideaCVS is trading above the supporting moving averages. Heading higher. Longby bhoweUpdated 112
CVS Health Corporation (CVS)Empresa ofrece servicio de salud y posee mas de 9800 farmacias en 49 estados de EEUU, luego de alcanzar un máximo viene de un retroceso... Longby AlainFiore1
$CVS Health Bullish but still in downtrend.Bullish run in 2019, but is becoming overbought, despite the gains in 2019 the stock is still in a long term downtrend and we would remains on the sidelines until that channel is broken. There is plenty of upside so need to jump in at the end of the current run, better entries will present themselves. 19.87 P/E ratio, very reasonable. 2.82% yield. Company profile CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.by Bullishcharts26
CVS moment of truth is comingCVS has been headed toward the top of its parallel channel. It's currently overbought, so its first test of the channel top may get rejected. However, expect a breakout soon after. CVS is my favorite investment thesis in the entire market right now. The company is opening 1500 HealthHub stores by the end of 2021 and is also completing a merger with Aetna. Its earnings are expected to grow, and the stock is absurdly undervalued. Fair value based on forward P/E for 2021 is something like $95 per share. Even based on this year's P/E, it should be at least $79. (I base these numbers on the Zack's "Price and Consensus" chart, which is one of my favorite tools for fundamental analysis. We'll do an educational episode on this on the "Wall Street Petting Zoo" Youtube channel next week.)Longby ChristopherCarrollSmith14
CVS LONGFrom a long term perspective, CVS is definitely a mover to watch. $70 is a big level for them to reclaim. I am buying some shares at $70 and holding for now. I expect further growth that will push us out of this channel in the upcoming yearLongby xx808Traderz115
Looks great LT above the trendline IMOShould do 70's to start, above 80 would be greatLongby KasukuInvestments1
CVS Health Corp Stop Heartburn Drug Sales Over Cancer LinksCVS Health Corp (NYSE: CVS), Walgreens Boots Alliance Inc. (NASDAQ: WBA) and Rite Aid Corporation (NYSE: RAD) had mixed fortunes in the market. This is after announcing they will no longer sell a heartburn medication suspected of containing a cancer-causing substance. Zantac is the heartburn medication on the spotlight on the Food and Drug Administration, raising the red flag. Zantac Cancer Links The FDA in a press release has warned that the drug could contain low levels of nitrosamine, an impurity categorized as a human carcinogen. CVS Health stock was up 1.59% while Walgreens stock rallied 1.65% and Rite Aid plunged 4.53% after announcing the withdrawal of Zantac from shelves. Rite Aid has confirmed it is in the process of removing the drug from its shelves as well as other generic version sold under its brand name. Walgreens and CVS have since confirmed that customers would purchase Zantac can return the medication for a refund. However, the companies insist the FDA has not recalled the drug. Novartis AG (NYSE: NVS) is another pharmaceutical company dragged into the ranitidine standoff. The company has also stopped selling a prescription form of ranitidine as it awaits the FDA’s ongoing investigation. GlaxoSmithKline plc. (NYSE: GSK) has also stopped the distribution of a generic version of the drug. Sanofi SA (NASDAQ: SNY), which is the company behind Zantac, was up 0.15% even as the giant pharmaceutical companies announced they would no longer sell the drug. The drugmaker, in its defense, maintains that the levels of contaminants found by the FDA barely exceed the levels found in foods. The environmental contaminant is mostly found in water and foods as well as meats and dairy products. In high levels, the contaminant can trigger tumors in the liver as well as other organs. In humans, they can lead to cancer. FDA Ranitidine And Zantac Probe The FDA is currently investigating a number of ranitidine drugs as well as Zantac on concerns that they contain high levels of nitrosamine impurity that can trigger cancer cells in the human body. The agency is also investigating the possible cause of contamination as well as the potential risk of the impurity to patients. However, the agency is yet to issue an order prohibiting the sale of Zantac drug. Sales suspension by the pharmaceutical giants is thus a precautionary measure awaiting the outcome of the ongoing trials by the agency. “The FDA is not calling for individuals to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options,” FDA in a statement. Instead of taking Zantac and other OTC ranitidine, the FDC is urging people to take other OTC approved medicines for their conditions. The European Medicines Agency has already joined the FDA in reviewing the drug. Canada, on its part, has stopped the sale of all ranitidine drugs awaiting the ongoing investigations. by Sector_Reports3
CVS Health Corp on verge of Golden Cross===Entry level $60 - Price target $70=== Stock at a juncture, we await a strong buy signal from a golden cross of 50 & 200 MA's. RSI strong but has hit mid channel support and needs a reset. AVERAGE ANALYSTS PRICE TARGET $70 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT P/R RATIO 17 SHORT INTEREST 2% COMPANY PROFILE CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.by RedHotStocks22